Market Overview

EC Approves Gilead's Viread for HIV-1 Infection in Children, Adolescents

Share:
Related GILD
15 Biggest Mid-Day Losers For Tuesday
Technical Alert - Gilead Sciences Falls Into Limited Support Zone After Q2 Report
The Vetr community has upgraded $GILD to 4.5-Stars. (Vetr)

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission has granted marketing authorization for two new indications for once-daily Viread^® (tenofovir disoproxil fumarate). The first new indication permits the use of Viread in combination with other antiretroviral agents for the treatment of HIV-1 infected pediatric patients aged 2 to less than 18 years with nucleoside reverse transcriptase inhibitor (NRTI) resistance or toxicities precluding the use of first line pediatric agents. Additionally, Viread is now approved for the treatment of chronic hepatitis B virus (HBV) infection in adolescent patients aged 12 to less than 18 years with compensated liver disease and evidence of immune active disease. Today's authorization covers all 27 countries of the European Union (EU). Viread was approved for use in combination with other antiretroviral agents as a treatment for HIV-1 infection in adults and for chronic HBV in 2002 and 2008, respectively, and is the most-prescribed molecule for these diseases in major European countries.

Posted-In: News

 

Related Articles (GILD)

View Comments and Join the Discussion!